Founded in 1998, ProQuest Investments is a healthcare venture capital firm with over $875 million under management. We have 12 deal professionals and three offices, our headquarters in Princeton, and additional offices in San Diego and Montreal.
We invest in healthcare companies seeking financings ranging from seed to late-stage. Our portfolio reflects the rich diversity of the healthcare industry and exemplifies our commitment to fostering the growth of exceptional businesses. In addition to our breadth of experience across many sectors of the healthcare industry, we have special expertise in therapeutics, where innovations in drug discovery technologies and molecular analysis are transforming an enormous unmet medical need. With a proven superior track record and over 40 investments in such diverse therapeutic categories as oncology, pain and infectious disease, ProQuest Investments seeks to build long term, mutually beneficial partnerships with outstanding entrepreneurs.
At the end of 2006, ProQuest Investments closed its fourth fund of $425 million.
|Mersana Therapeutics||7/12||Series A||$27M||4|
|Agile Therapeutics||7/12||Series C||$40M||6|
|Mevion Medical Systems||1/12||Venture Round||$45M||3|
|Immune Design||7/10||Series B||$32M||4|
|ReVision Optics||7/10||Series D||$35M||4|
|Predictive Biosciences||6/10||Series C||$25M||5|
|Gloucester Pharmaceuticals||8/09||Series D||$29M||5|
|Zosano Pharma||8/09||Series B||$30M||4|
|Clovis Oncology||5/09||Series A||$145M||7|
|Gemin X Pharmaceuticals||7/08||Series C||$38M||13|
|Excaliard Pharmaceuticals||11/07||Series A||$15.5M||3|
|Zosano Pharma||11/07||Series A||$90M||4|
|LEAD Therapeutics||11/07||Series A||$17M||3|
|Mersana Therapeutics||11/05||Venture Round||$21M||7|
|EUSA Pharma||7/05||Venture Round||$14M||2|